☆ 4.5 Article

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?

DERMATOLOGIC THERAPY (2022)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa

Trinidad Montero-Vilchez et al.

Summary: The study describes the clinical experience of switching from adalimumab originator to biosimilar and back again. Switching to biosimilar can lead to efficacy and adherence issues, while switching back to the original drug can resolve most problems, though some patients may lose confidence and discontinue treatment. Evaluating the benefit-risk ratio is important when switching HS patients.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Letter Dermatology

Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting

S. Ribero et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Letter Dermatology

Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre

Giuseppe Gallo et al.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa

Federica Ricceri et al.

DERMATOLOGIC THERAPY (2020)

添加到收藏夹

Letter Dermatology

Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa

Sharmila Patil

INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2018)

添加到收藏夹

Article Dermatology

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

C. C. Zouboulis et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

添加到收藏夹

Article Dermatology

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

A. B. Kimball et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)

添加到收藏夹

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?

相关参考文献

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa

Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting

Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre

Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa

Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

导出引文

分享论文